Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRFTB5)

• Drug Name: Cis-4-hydroxytamoxifen Drug Info
• Synonyms: Afimoxifene, E-isomer; E-4-Hydroxytamoxifen; AKE3PH0IML; SCHEMBL2132301; SCHEMBL640496; ZINC1530090; cis-4-Hydroxytamoxifen; cis/trans-4-Hydroxytamoxifen; (E)-4-Hydroxytamoxifen; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)-phenyl)-2-phenylbut-1-en-1-yl)phenol; 174592-47-3; 4-((1E)-1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; AC1NS1S8; ACM174592473; AKOS015894466; API0000886; BCP9000165; BCP9000243; CHEBI:92076; CHEMBL279301; CP-0071; DTXSID10169854; HY-16950B; UNII-AKE3PH0IML
• Cross-matching ID:
  PubChem CID: 5352135
  ChEBI ID: CHEBI:92076
  CAS Number: CAS 174592-47-3
  TTD Drug ID: DMRFTB5
  INTEDE Drug ID: DR1940

Molecule-Related Drug Atlas

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[2]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[3]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[5]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[6]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[7]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[8]
Metronidazole	DMTIVEN	Abscess		Approved	[9]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[10]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[11]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A8 (UGT1A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[12]
Empagliflozin	DMRF9YK	Type-1 diabetes	5A10	Approved	[13]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[14]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]
Afimoxifene	DMFORDT	Breast cancer	2C60-2C65	Phase 2	[1]
EUGENOL	DM7US1H	Discovery agent	N.A.	Patented	[15]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[15]
phloretin	DMYA50U	Discovery agent	N.A.	Investigative	[15]
Anthraflavic acid	DMN1YFU	N. A.	N. A.	Investigative	[15]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[1]
UDP-glucuronosyltransferase 1A8 (UGT1A8)	DE2GB8N	UD18_HUMAN	Substrate	[1]

References

• [1] Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
• [2] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [3] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [4] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [5] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [6] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [7] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [8] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [9] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [10] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [11] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [12] Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
• [13] Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
• [14] Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
• [15] Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.